<DOC>
	<DOCNO>NCT02688491</DOCNO>
	<brief_summary>Whether patient stage III clear cell renal cell carcinoma ( ccRCC ) receive adjuvant target therapy still debate . The investigator invent assay consist 5 CpGs : cg00396667（PITX1） , cg18815943 （FOXE3） , cg03890877（TWF2） , cg07611000 （EHBP1L1）and cg14391855（RIN1）that successfully categorise patient stage III clear cell renal cell carcinoma high-risk low-risk group Harzard Ratio ( HR ) 4.93 . Here investigator randomly assign assay-defined high risk patient locally advance ccRCC adjuvant target therapy group observation group.Disease free survival overall survival end point observation .</brief_summary>
	<brief_title>A CpG-methylation-based Assay Stratifying Stage III Clear Cell Renal Cell Carcinoma Receiving Adjuvant Treatment</brief_title>
	<detailed_description>The investigator ' CpG-methylation-based assay contain 5 CpGs : cg00396667（PITX1） , cg18815943 （FOXE3） , cg03890877（TWF2） , cg07611000 （EHBP1L1）and cg14391855（RIN1） . The investigator evaluate CpG methylation status surgical specimen use pyrosequencing calculate risk score [ risk score= ( 0.0066×PITX1 ) + ( 0.0034×FOXE3 ) － ( 0.027×TWF2 ) － ( 0.018×EHBP1L1 ) － ( 0.03×RIN1 ) ] , risk score ≥－0.1 assay-defined high risk status risk score＜－0.1 assay-defined low risk status . The investigator randomly assign assay-defined high risk patient stage III ccRCC intervention group control group . The intervention group receive adjuvant target therapy control group deserve observation . Primary endpoint disease free survival overall survival .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>The informed consent obtain patient . With confirmed diagnosis stage III clear cell renal cell carcinoma With moderate/good ECOG health rating ( PS ) : 01 score . The patient receive anticancer treatment primary surgery . The patient receive radical operation renal cancer negative margin . With severe comorbidities , cardiovascular disease , chronic obstructive pulmonary disease , diabetes mellitus , chronic renal dysfunction . With bad compliance contraindication enrollment . Pregnant woman lactate woman . With contraindication receive adjuvant target therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>